Confronting the major communicable diseases linked to poverty

1. Confronting the major communicable diseases linked to poverty Health Directorate F3 unit: Poverty related Diseases Anne Degrand-Guillaud EoI assesment and presentation NCP 24 October 2002

2. Priority 1 Life sciences, genomics and biotechnology for health • Functional genomics (fundamental knowledge) • Genomics and biotechnology for health • Genomic approaches to medical knowledge • Cancer • Major communicable diseases linked to poverty EoI assesment and presentation NCP 24 October 2002

3. Poverty related diseases EDCTP Research projects Integrated projects Network of excellence Three major communicable diseases HIV/AIDS, TB, Malaria European and developing countries clinical trials partnership EoI assesment and presentation NCP 24 October 2002

4. EDCTP Overall aim: to develop a long-term partnership between Europe and Developing Countries to fight HIV/AIDS, Tuberculosis and Malaria through new clinical interventions Scope: • Network of national programmes • Clinical trials (drugs, vaccines) conducted in Africa • Capacity building in DCshttp://europa.eu.int/comm/research/info/conferences/edctp/edctp_en.html EoI assesment and presentation NCP 24 October 2002

5. Global features of EDCTP • Long-term sustainable initiative (10-20 years) • Shared ownership of European and Developing Countries • Dynamic structure with balanced involvement of different stakeholders (DC, MS, Commission, WHO, Industry, International Organisations) • Integration of European National Programmes • Significant Community contribution during the next 4 years: 200 M€ EoI assesment and presentation NCP 24 October 2002

6. Overall Research Strategy of the 6th Framework Programme to confront HIV/AIDS, Malaria and Tuberculosis EUROPEAN DEVELOPING COUNTRIES CLINICAL TRIALS PARTNERSHIP (EDCTP) Clinical Trials (Phase II/III) HIV/AIDS Malaria TB Phase I trials NEW INSTRUMENTS Pre-clinical • Vaccines • Drugs • Vaccines • Microbicides • Vaccines • Drugs Discovery CROSS-CUTTING TOPICS Genomics H I G H R I S K P R O J E C T S EoI assesment and presentation NCP 24 October 2002

7. Confronting the major communicable diseases linked to poverty High level of interest, excellent quality of the EoI: most EU leading researchers represented in one or more EoI EoI assesment and presentation NCP 24 October 2002

8. EoIs Panel general recommendations (1) • Encourage participation of partners from DC • Stimulate the training component both for the North and the South • Increase the professionalism of management • Include in the projects pre-clinical testing in non-human primates and GMP production of candidate drugs or vaccines EoI assesment and presentation NCP 24 October 2002

9. EoI’s Panel general recommendations (2) • Several EoI covered activities of valuable support for the EDCTP, these should be considered for integration in the EDCTP actions • A limited number of high-risk innovative research project should be made available to underpin and ensure the full success of the new instruments EoI assesment and presentation NCP 24 October 2002

10. Vaccines innovative approaches develop candidates up to phase I Microbicides systematic studies using a biologically-defined approach 1st calls Vaccines Microbicides Forthcoming calls Therapy Trials in Europe HIV/AIDS Topics prioritized in EoI Topics included in WP EoI assesment and presentation NCP 24 October 2002

11. HIV-AIDS Development of an HIV vaccine • innovative approach to new promising vaccine candidates including partners from DC • up to clinical testing in human (phase I) HIV microbicides • a biologically defined approach targeting HIV receptors to develop new candidates up to phase I clinical trials. • of wide acceptability for empowering women in developing countries EoI assesment and presentation NCP 24 October 2002

12. 1st call Biology and Pathology of Malaria parasite Forthcoming calls Vaccines Drugs Malaria Topics prioritized in EoI Topics included in WP Biology and Pathology of Malaria parasite direct relevance for search of new drugs, vaccines and diagnostics • Vaccines • integration of EU research groups • rational approach for development of new candidates • Drugs • exploitation of the genomic information EoI assesment and presentation NCP 24 October 2002

13. Malaria Biology and pathology of the malaria parasite • to ensure coherence and full exploitation of European synergies • to understand the biology of the parasite, the human host-parasite and mosquito-parasite interactions • to be of direct relevance for new drugs, vaccines and diagnostics EoI assesment and presentation NCP 24 October 2002

14. Vaccines stimulate direct involvement of DC strengthen management Drugs exploiting the genome sequence information 1st call Vaccines Forthcoming calls Drugs Tuberculosis Topics prioritized in EoI Topics included in WP EoI assesment and presentation NCP 24 October 2002

15. Tuberculosis Tuberculosis vaccine development • to develop new candidates vaccines • pre clinical testing in non human primates up to phase I clinical trials and GMP production EoI assesment and presentation NCP 24 October 2002

16. Mucosal vaccines for PRD focus on HIV and TB Neonatal vaccination strategies for PRD focus on neonatal vaccines Dendritic cells and Innate immunity high relevance in several action lines in priority 1 1st calls Mucosal vaccines Forthcoming calls Neonatal vaccination strategies for PRD Cross-cutting topics Topics prioritized in EoI Topics included in WP EoI assesment and presentation NCP 24 October 2002

17. Cross-cutting topics Development of mucosal vaccines for poverty-related diseases • to clarify the basic principles of mucosal immunity • to bring candidate vaccines (TB and HIV) to phase I trials EoI assesment and presentation NCP 24 October 2002